#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Medulloblastoma Arteriovenous malformation Acute myeloid leukaemia recurrent Restless legs syndrome Methylmalonic acidaemia Immunodeficiency Necrotising myositis Neonatal asphyxia Small for dates baby Measles Haemophilia Marginal zone lymphoma recurrent Astrocytoma Oesophageal adenocarcinoma stage II Penile squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Hereditary hypophosphataemic rickets – Basic Information Indolent systemic mastocytosis – Diagnostics Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Usher’s syndrome – Basic Information Erdheim-Chester disease – Basic Information Von Willebrand’s disease – Basic Information Haemophilia B with anti factor IX – Trials in Disease Mucopolysaccharidosis III – Basic Information Rhabdomyosarcoma recurrent Pleomorphic leiomyosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gen3017 Mogamulizumab Asfotase Alfa Mifamurtide TEV-53408 Thiocolchicoside Umeclidinium Clomifene Citrate Gskvx000000017033 Cdr132L Stx-241 NALOXEGOL INOBRODIB Urapidil Vh4524184 Human Vaccinia Immunoglobulin Pyrimethamine Caffeine IMB 101 Emicizumab More therapies…

    Learn about Your Condition

    Exfoliation glaucoma Choroid melanoma Rhinitis allergic Post procedural swelling Bacteraemia Schizophreniform disorder Lymphoma Tumour thrombosis Blood disorder Diarrhoea Gaucher's disease type III Femoral hernia Endometrial adenocarcinoma Macular degeneration Dengue fever More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Efficacy of intravenous prasinezumab versus placebo in Parkinson’s disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Prasinezumab
    • Sodium Chloride
    France Germany Italy Luxembourg Spain Sweden

  • Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Tislelizumab
    • Ramucirumab
    • Calcium Folinate
    Germany Italy Spain

  • Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • ADMILPARANT
    Austria Belgium Denmark Finland France Germany +8

  • Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

    Not yet recruiting

    4 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Germany

  • Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cemiplimab
    The Netherlands

  • Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Acetazolamide
    France
Previous Page
1 … 693 694 695 696 697 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!